BioSpace News Archive

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced that it will present virtually at The Liver Meeting Digital Experience TM 2020, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held from November 13-16, 2020. The

A research team at McMaster University has developed a self-cleaning surface that instantly repels viruses and bacteria – and could potentially prevent the transfer of superbugs.

Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35 th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020) Atara’s allogeneic CAR T therapy leverages the combination of cell intrinsic PD1DNR checkpoint inhibition and 1XX CAR signaling technologies built on the Company’s novel EBV T-cell platform

Oramed Pharmaceuticals Inc. announced that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific Officer Dr. Miriam Kidron will join Premas Biotech’s Co-Founder and Managing Director Dr. Prabuddha Kundu and Co-Founder and Chief Operating Officer Dr. Nupur Mehrotra in Part 2 of a webinar titled “Oral Delivery of Therapeutic Proteins - Oramed Story” on Wednesday, November 18, 2020 at 10:00 a.m. ET.

Signifier Medical Technologies (“Signifier” or the “Company”), an innovator in the sleep-disordered breathing market, is pleased to announce the appointment of Jim Hinrichs to the Board of the Company. He joins existing Directors Kieran Gallahue (Chairman), Akhil Tripathi (CEO), Steffen Kastner and Robert Sullivan.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and COO of Agenus, and Patrick Jordan, COO of AgenTus Therapeutics

Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today reported topline results from its Phase IV clinical trial of its in-license eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome.

OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company commercializing a second generation fiber optic pressure guidewire to diagnose and treat coronary disease, has scheduled a

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its Q3 2020 financial results and provides a business update.

Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the presentation of preclinical data of its lead investigational therapies: XTX201, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4 antibody